Sam Paullin has experience in a wide range of securities matters, including representing issuers and underwriters in initial public offerings, public secondary follow-ons, de-SPACs and private debt offerings.
Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
Prelude Therapeutics – $100 Million Follow-on Offering
May 18, 2023
Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.
Cooley advised the underwriters in Vivid Seats’ $128 million follow-on offering. Vivid Seats is an online ticket marketplace connecting fans to live events and artists. As the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theaters and comedy, Vivid Seats operates in two segments – marketplace and resale. Lawyers Christina Roupas, Courtney Tygesson, Grady Chang, Sam Paullin, Leah Duncan and Adam Bloom led the Cooley team.
Geron Corporation – $227.8 Million Follow-on Offering
January 5, 2023
Cooley advised Geron Corporation, a late-stage biopharmaceutical company in California pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies, on its $227.8 million follow-on offering. Partners Chadwick Mills and Kristin VanderPas led the Cooley team.